why choose us

First received: May 18, 2023

Clinical Trial: Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsing Multiple Sclerosis

Study Type: INTERVENTIONAL


Official Title: Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

Brief Summary: The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.

Read more